Table 1. Main clinical features and prevalence of diabetes mellitus (DM) in recent randomized AF trials with novel non-vitamin K antagonist oral anticoagulants.
| Study | RE-LY | ROCKET-AF | ARISTOTLE | ENGAGE-AF |
|---|---|---|---|---|
| Drug | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
| Age >75 years | 40% | 43.7% | 31.2% | 40.5% |
| CHADS2 mean | 2.2 | 3.48 | 2.1 | 2.8 |
| Previous TIA/stroke | 20.3% | 54.9% | 19.2% | 28.1% |
| Hypertension | 78.9% | 90.3% | 87.3% | 93.7% |
| Diabetes | 23.3% | 39.9% | 25% | 36.4% |
| CHF | 31.8% | 62.6% | 35.5% | 58.2% |
AF, atrial fibrillation; CHF, chronic heart failure; TIA, transient ischaemic attack; CHADS2, cardiac failure, hypertension, age, diabetes, stroke (doubled).